Persistence of infarct zone T2 hyperintensity at 6 months after acute ST-elevation myocardial infarction: incidence, pathophysiology and prognostic implications by Carberry, Jaclyn et al.
1In survivors of acute ST-segment–elevation myocar-dial infarction (STEMI), edema within the infarct zone 
revealed by T2-weighted cardiac magnetic resonance 
(CMR) imaging1,2 is associated with the initial extent of 
myocardial jeopardy,3 the size of infarction,4 and prog-
nosis in the longer term.5 Edema impairs myocardial 
contractility by reducing the binding efficiency of actin–
myosin filaments leading to reduced force generation in 
affected cardiomyocytes.6
Background—The incidence and clinical significance of persistent T2 hyperintensity after acute ST-segment–elevation 
myocardial infarction (STEMI) is uncertain.
Methods and Results—Patients who sustained an acute STEMI were enrolled in a cohort study (BHF MR-MI: NCT02072850). 
Two hundred eighty-three STEMI patients (mean age, 59±12 years; 75% male) had cardiac magnetic resonance with 
T2 mapping performed at 2 days and 6 months post-STEMI. Persisting T2 hyperintensity was defined as infarct T2 
>2 SDs from remote T2 at 6 months. Infarct zone T2 was higher than remote zone T2 at 2 days (66.3±6.1 versus 
49.7±2.1 ms; P<0.001) and 6 months (56.8±4.5 versus 49.7±2.3 ms; P<0.001). Remote zone T2 did not change over 
time (mean change, 0.0±2.7 ms; P=0.837), whereas infarct zone T2 decreased (−9.5±6.4 ms; P<0.001). At 6 months, 
T2 hyperintensity persisted in 189 (67%) patients, who were more likely to have Thrombus in Myocardial Infarction 
flow 0 or 1 in the culprit artery (P=0.020), incomplete ST-segment resolution (P=0.037), and higher troponin (P=0.024). 
Persistent T2 hyperintensity was associated with NT-proBNP (N-terminal pro-B-type natriuretic peptide) concentration 
(0.57 on a log scale [0.42–0.72]; P=0.004) and the likelihood of adverse left ventricular remodeling (>20% change in left 
ventricular end-diastolic volume; 21.91 [2.75–174.29]; P=0.004). Persistent T2 hyperintensity was associated with all-
cause death and heart failure, but the result was not significant (P=0.051). ΔT2 was associated with all-cause death and 
heart failure (P=0.004) and major adverse cardiac events (P=0.013).
Conclusions—Persistent T2 hyperintensity occurs in two thirds of STEMI patients. Persistent T2 hyperintensity was 
associated with the initial STEMI severity, adverse remodeling, and long-term health outcome.
Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT02072850.   
(Circ Cardiovasc Imaging. 2017;10:e006586. DOI: 10.1161/CIRCIMAGING.117.006586.)
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2  Carberry et al  Persistent T2 Hyperintensity Post-STEMI
There is uncertainty about the natural history and clinical 
significance of persistently high infarct zone T2 values because 
previous studies were limited by sample size (n=10–62),7–10 or 
method of detection,7,8 for example, T2-weighted short inversion 
time inversion recovery (STIR) imaging. Contemporary quanti-
tative T2-mapping techniques have better diagnostic accuracy11 
and repeatability12 compared with T2-weighted STIR imaging.
Our aims were to (1) measure infarct zone T2 (ms) and 
its changes over time in a longitudinal study of acute STEMI 
patients; (2) determine the incidence of persistent T2 hyperin-
tensity at 6 months post-STEMI; (3) assess the clinical char-
acteristics and left ventricular (LV) size and function of those 
patients with persistent T2 hyperintensity and compare them 
to those patients in whom T2 hyperintensity had resolved; and 
(4) assess the association of persisting T2 hyperintensity with 
longer-term health outcome.
We hypothesized that the persistence of myocardial infarct 
zone T2 hyperintensity would be associated with the initial 
STEMI severity, and it would be associated with surrogate 
measures of outcome, including LV volume and NT-proBNP 
(N-terminal pro-B-type natriuretic peptide), and longer-term 
health outcome.
Methods
The full methodology has been reported previously (BHF MR-
MI [Detection and Significance of Heart Injury in ST Elevation 
Myocardial Infarction]: NCT02072850) and is detailed in the 
Methods in the Data Supplement. Patients with acute STEMI were 
consecutively screened for suitability and those recruited provided 
written informed consent. The study was approved by the National 
Research Ethics Service (Reference 10-S0703-28) and was publically 
registered (NCT02072850). The data, analytic methods, and study 
materials will be made available to other researchers for purposes of 
reproducing the results or replicating the procedure.13
CMR Image Analyses
Myocardial Edema
CMR images were analyzed on a Siemens workstation. The epicardial 
and endocardial contours on the last corresponding T2-weighted raw 
image with an echo time of 55 ms were planimetered and copied to 
the T2 map.14 Regions of interest were drawn in the remote and infarct 
zones to measure the respective signal intensities. T2 hyperintensity 
was present if the T2 signal in the infarct zone was 2 SDs above the 
T2 signal in the remote zone.11,15 Areas of microvascular obstruction 
or hemorrhage, identified by consulting late gadolinium enhancement 
and T2* images, respectively, were excluded from the infarct region of 
interest because this would reduce the signal intensity and may mask 
the presence of T2 hyperintensity. The remote zone was drawn 180° 
from infarcted myocardium, midmyocardial, and ≈1 segment in length. 
Measurement was performed on multiple slices and the average taken.
Infarct Definition and Size
The territory of infarction was delineated using a signal intensity 
threshold of >5 SD above a remote reference region and expressed as 
a percentage of total LV mass.16
Myocardial Salvage
Myocardial salvage was calculated by subtraction of percent infarct 
size from percent myocardial edema.5,17,18 The myocardial salvage in-
dex was calculated by dividing the myocardial salvage area by the 
initial extent of edema.
Adverse Remodeling
Adverse remodeling was defined as an increase in LV end-diastolic 
volume at 6 months from baseline by ≥20%.19
Health Outcomes
We prespecified adverse health outcomes that are pathophysiologi-
cally linked with STEMI. The primary composite outcome was 
major adverse cardiac events (MACE) defined as cardiac death, non-
fatal myocardial infarction, or heart failure hospitalization after the 
6-month CMR scan. All-cause death or heart failure (heart failure 
hospitalization or defibrillator implantation) after the 6-month CMR 
scan was a secondary outcome.
Statistics
The full statistical methods are reported in the Data Supplement. All 
P values were 2-sided. A P value >0.05 indicated the absence of a 
statistically significant effect. Analyses were performed using SPSS 
version 22 for Windows (SPSS, Inc, Chicago, IL) or R v3.3.0.
Results
Of 343 STEMI patients referred for emergency percutaneous 
coronary intervention, 283 (87%) patients with paired scans 
were included in the final analyses. The flow diagram for the 
study is shown in Figure I in the Data Supplement.
Patient Characteristics
Using T2 mapping, 189 (67%) patients had persistent T2 
hyperintensity at 6 months post-STEMI.
Patient characteristics are shown in Table 1. The mean age 
was 59±11 years, and 75% were male. Patients with persisting 
T2 hyperintensity were more likely to present with Thrombus in 
Myocardial Infarction flow 0 or 1 in the culprit artery (Thrombus 
in Myocardial Infarction flow 0 and 1: 61 [64%] without ver-
sus 144 [76%] with persisting T2 hyperintensity; Thrombus 
in Myocardial Infarction flow 2: 18 [19%] versus 34 [18%]; 
Thrombus in Myocardial Infarction flow 3: 15 [16%] versus 11 
[6%]; P=0.020). They were more likely to have partial resolu-
tion of the ST-segment postreperfusion (none: 15 [16%] versus 
26 [14%]; partial: 25 [27%] versus 79 [42%]; complete: 54 
[57%] versus 83 [44%]; P=0.037) and had higher troponin levels 
post-STEMI (1126 [155–3814] versus 2095 [122–5550] ng/L; 
P=0.024). Other clinical characteristics of patients with and 
without persisting T2 hyperintensity were similar (P>0.050).
CMR Findings
During the Index Hospitalization
CMR findings are summarized in Table 2 and Table I in the Data 
Supplement. Exemplar clinical cases are included in Figure 1. 
At 2 days, the T2 signal in the infarct zone was higher than in 
the remote zone (66.3±6.1 versus 49.7±2.1 ms; P<0.001).
Patients with persisting T2 hyperintensity had higher 
LV volumes, more extensive infarcts, and lower myocardial 
salvage indexes (Table 2). They were more likely to have 
microvascular obstruction, a larger extent of microvascular 
obstruction, and T2 signal and extracellular volume in the 
infarct zone were significantly higher than in those without 
persisting T2 hyperintensity (Table 2). There was an associa-
tion between the extent of microvascular obstruction and the 
extent of myocardial edema at 2 days (0.21% [0.17%–0.25%]; 
P<0.001) and a trend to association in the extent of myocar-
dial edema at 2 days post-STEMI and the persistence of T2 
hyperintensity (Table 2). There was no difference in T1 or T2 
core signal between patients with and without persisting T2 
hyperintensity (Table I in the Data Supplement).
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3  Carberry et al  Persistent T2 Hyperintensity Post-STEMI
The results of interobserver agreement of infarct 
zone T2 measurements are shown in Figure II in the Data 
Supplement.
At 6 Months
T2 remained higher in the infarct zone compared with the 
remote zone at 6 months (56.8±4.5 versus 49.7±2.3 ms; 
P<0.001). Remote zone T2 did not change between day 2 
and 6 months (mean change, 0.0±2.7 ms; P=0.837), whereas 
infarct zone T2 decreased (−9.5±6.4 ms; P<0.001; Figure 2). 
Patients with persistent T2 hyperintensity had a smaller 
reduction in infarct zone T2 (−8.8±6.6 versus −10.9±6.0 ms; 
P=0.010). The change in infarct zone T2 was associated with 
the extent of microvascular obstruction at 2 days (0.20% 
[0.08%–0.33%]; P=0.002).
At 6 months, those with persisting T2 hyperintensity had 
lower LV ejection fractions and larger LV volumes. Infarct 
size remained larger in those with persisting T2 hyperinten-
sity, and infarct zone CMR parameters were higher (T1, T2, 
and extracellular volume; Table 2). Remote zone T2 signal 
was lower in those with persisting T2 hyperintensity, whereas 
remote zone T1 signal was the same (Table 2; Table I in the 
Data Supplement).
   Left circumflex 49 (17)
   Right coronary 129 (46)
  Culprit artery TIMI flow grade at initial angiography, n (%)
   0/1 205 (72)
   2 52 (18)
   3 26 (9)
  Culprit artery TIMI flow grade post-PCI, n (%)
   0/1 4 (1)
   2 9 (3)
   3 270 (95)
Blood results on admission
  C-reactive protein, mg/L, median  
(Q1, Q3), range
3.0 (2.0, 7.0), 0–125.0
  NT-proBNP, pg/mL, median (Q1, Q3), 
range
767 (334, 1633), 29–19 521
  Troponin I, ng/L, median (Q1, Q3), range 1710 (141, 5229), 0–28 406
Data are given as n (%), mean±SD, or median (Q1, Q3) as appropriate. ACE-I 
indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor 
blocker; BMI, body mass index; NT-proBNP, N-terminal pro-B-type natriuretic 
peptide; PCI, percutaneous coronary intervention; and TIMI, Thrombolysis in 
Myocardial Infarction.
*History of diet-controlled or treated diabetes mellitus.
†Successfully electrically cardioverted ventricular fibrillation at presentation 
or during PCI.
‡Killip classification of heart failure post-STEMI: class I—no heart failure, 
class II—pulmonary rales or crepitations, third heart sound, and elevated 
jugular venous pressure, class III—acute pulmonary edema, and class IV—
cardiogenic shock.
§No. of stenoses ≤50% of the reference vessel diameter by visual assessment 
and if there was left main stem involvement.
Table 1. Continued
Characteristics All Patients; n=283
Table 1. Characteristics of 283 Patients With Acute STEMI
Characteristics All Patients; n=283
Age, y 59±11
Male, n (%) 211 (75)
BMI, kg/m2 29±5
Hypertension, n (%) 94 (33)
Current smoking, n (%) 167 (59)
Hypercholesterolemia, n (%) 80 (28)
Diabetes mellitus*, n (%) 32 (11)
Previous angina, n (%) 34 (12)
Previous myocardial infarction, n (%) 14 (5)
Previous PCI, n (%) 11 (4)
Medical therapy
  Aspirin, n (%) 282 (99)
  Clopidogrel, n (%) 281 (99)
  β-blocker, n (%) 269 (95)
  ACE-I or ARB, n (%) 279 (99)
  Statin, n (%) 283 (100)
Presenting characteristics
  Heart rate, bpm 77±17
  Systolic blood pressure, mm Hg 135±24
  Diastolic blood pressure, mm Hg 79±14
  Symptom onset to reperfusion, min 248±207
  Ventricular fibrillation†, n (%) 17 (6)
  Killip class‡, n (%)
   I 209 (74)
   II 56 (20)
   III/IV 18 (6)
ECG
  ST-segment resolution post-PCI, n (%)
   Complete, ≥70% 137 (49)
   Incomplete, 30% to <70% 104 (37)
   None, ≤30% 41 (15)
Coronary angiography
  Reperfusion strategy, n (%)
   Primary PCI 265 (94)
   Rescue PCI (failed thrombolysis) 12 (4)
   Successful thrombolysis 6 (2)
  No. of diseased arteries§, n (%)
   1 152 (54)
   2 87 (31)
   3 38 (13)
   Left main 6 (2)
  Culprit artery, n (%)
   Left anterior descending 105 (37)
(Continued )
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4  Carberry et al  Persistent T2 Hyperintensity Post-STEMI
Table 2. CMR Findings in 283 Patients Grouped According to the Presence or Absence of Persistent T2 
Hyperintensity Revealed by T2 Mapping at 6 Months Post-STEMI
Characteristics
All Patients;  
n=283
No Persistent T2 
Hyperintensity;  
n=94 (33%)
Persistent T2 
Hyperintensity;  
n=189 (67%) P Value*
CMR findings 2 days post-STEMI
  LV end-diastolic volume, mL
   Men 161±31 155±30 164±31 0.036
   Women 124±25 130±23 121±25 0.172
  LV end-systolic volume, mL
   Men 74±26 69±25 78±26 0.014
   Women 54±18 57±18 52±17 0.225
  LV mass, g
   Men 144±33 137±29 148±34 0.028
   Women 97±21 101±17 95±23 0.216
Edema and infarct characteristics
  Myocardial edema, % LV mass 32±12 30±13 33±11 0.050
  Infarct size, % LV mass 18±13 13±13 20±13 <0.001
  Myocardial salvage, % LV mass 19±9 21±10 18±8 0.033
  Myocardial salvage index, % LV mass 63±24 73±24 58±23 <0.001
  Late microvascular obstruction present, n (%) 138 (49) 33 (35) 105 (56) 0.002
  Late microvascular obstruction, % LV mass 2.6±4.6 1.5±3.6 3.1±4.9 0.004
Myocardial T1, T2, and ECV values
  T1 hypointense core present, n (%) 137 (48) 33 (35) 104 (55) 0.002
  T2 infarct, ms 66.3±6.1 64.4±5.7 67.3±6.1 <0.001
  T2 hypointense core present, n (%) 165 (58) 41 (44) 124 (66) 0.001
  ECV infarct, % 56.0±11.7 52.8±12.9 57.7±10.7 0.024
CMR findings at 6 mo
  LV ejection fraction at 6 mo, % 62±9 65±8 61±10 <0.001
  LV end-diastolic volume at 6 mo, mL
   Men 169±42 151±31 177±45 <0.001
   Women 127±30 125±22 128±34 0.627
  LV end-systolic volume at 6 mo, mL
   Men 68±35 54±19 74±38 <0.001
   Women 46±18 45±18 47±18 0.550
  Adverse remodeling, n (%) 32 (12) 1 (1) 31 (17) <0.001
Infarct characteristics at 6 mo
  Infarct size at 6 mo, % LV mass 13±10 9±9 15±10 <0.001
Myocardial T1, T2 and ECV values at 6 mo
  T1 infarct at 6 mo, ms 1058±66 1035±59 1068±67 <0.001
  T2 remote at 6 mo, ms 49.7±2.3 50.3±2.5 49.4±2.1 0.001
  T2 infarct at 6 mo, ms 56.8±4.5 53.5±3.4 58.5±4.0 <0.001
  ECV infarct at 6 mo, % 51.6±11.1 47.5±11.0 53.7±10.5 <0.001
Data are given as n (%) or mean±SD as appropriate. Only variables with a significant difference between groups are reported. The 
full table is reported in the Data Supplement. CMR indicates cardiac magnetic resonance; ECV, extracellular volume; LV, left ventricle; 
STEMI, ST-segment–elevation myocardial infarction; T1, longitudinal relaxation time; and T2, transverse relaxation time.
*P values were obtained from 2-sample t test, Mann–Whitney test or Fisher exact test.
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5  Carberry et al  Persistent T2 Hyperintensity Post-STEMI
The higher the initial infarct zone T2 signal, the larger the 
decrease in infarct zone T2 signal by 6 months (Figure 3).
Persistent T2 Hyperintensity and LV Remodeling
Adverse remodeling occurred in 32 (12%) patients (Table 2). 
In a binary logistic regression analysis, persistent T2 hyper-
intensity was a multivariable associate of adverse remodeling 
(Table 3). When the change in infarct zone T2 (1 ms change and 
10 ms change) was included in place of persistent T2 hyper-
intensity at 6 months, this was also associated with adverse 
remodeling (Table 3). When the change in infarct zone extra-
cellular volume was included in the multivariable models, 
persistent T2 hyperintensity and change in infarct zone T2 were 
not associated with the change in LV end-diastolic volume.
Persistent T2 Hyperintensity and LV Function at 6 
Months
At 2 days, LV ejection fraction was similar between patients 
with and without persisting T2 hyperintensity, whereas 
6-month ejection fraction was lower in those with persisting 
T2 hyperintensity (Table 2). The mean change in LV ejection 
fraction was 6.7±7.8%. Patients with persisting T2 hyperinten-
sity had a numerically lower increase in LV ejection fraction 
without statistical significance (6.1±7.8% versus 7.9±7.7%).
Figure 1. Two patients with a similar presentation of acute anterior ST-segment–elevation myocardial infarction. Both patients were 
treated by percutaneous coronary intervention and with the same antithrombotic drugs. At the end of the procedure, both patients had 
Thrombus in Myocardial Infarction (TIMI) coronary flow grade 3 in the culprit left anterior descending artery. A, A patient with persistent 
infarct zone T2 hyperintensity: cardiac magnetic resonance (CMR) imaging was performed 2 days post-revascularization. T2 mapping 
revealed an infarct zone T2 value of 65 ms. CMR performed at 6 mo revealed a persistently high infarct zone T2 value of 66 ms in a 
matched myocardial slice position to baseline. Left ventricular (LV) end-diastolic volume increased from 143 to 175 mL at 6 mo represent-
ing adverse remodeling. This patient was readmitted with heart failure after the 6-mo CMR scan. B, A patient without persistent infarct 
zone T2 hyperintensity: CMR was performed 2 days post-revascularization. T2 mapping revealed an infarct zone T2 value of 63 ms. CMR 
performed at 6 mo revealed a lower infarct zone T2 value of 53 ms. LV end-diastolic volume decreased from 120 to 118 mL at 6 mo. This 
patient had an uncomplicated clinical course. MRI indicates magnetic resonance imaging.
Figure 2. Change in T2 signal in patients with ST-segment–elevation myocardial infarction with or without persisting infarct zone T2 
hyperintensity at 6 mo. Infarct zone T2 decreases in the majority of patients but to a lesser degree in patients with persisting edema.
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6  Carberry et al  Persistent T2 Hyperintensity Post-STEMI
The change in LV ejection fraction was associated with 
both persisting T2 hyperintensity and the change in infarct 
zone T2 (Table II in the Data Supplement).
Persistent T2 Hyperintensity and NT-proBNP
Blood samples were collected in the participants who were 
enrolled during office hours (n=123 patients at baseline and 
n=98 patients at follow-up). The characteristics of these patients 
were similar to the whole cohort (data not shown). Persistent 
T2 hyperintensity was associated with NT-proBNP at 6 months 
(0.57 on a log scale [0.42–0.72]; P=0.004), but not at baseline.
Persistent T2 Hyperintensity and Health Outcomes
Health outcome data were available in 283 (100%) patients. 
The median duration of follow-up was 1330 days (minimum–
maximum postdischarge censor duration 794–1622 days). 
All-cause death or heart failure occurred in 19 (7%) patients, 
including 7 noncardiovascular deaths, 4 cardiovascular 
deaths, 1 stroke death, 1 undetermined cause of death, and 
6 heart failure episodes. Sixteen (6%) patients experienced 
a MACE after the CMR scan at 6 months, including 6 heart 
failure episodes (Killip class 3 or 4 heart failure or defibrilla-
tor implantation), 4 cardiovascular deaths, 4 admissions with 
non-STEMI, and 2 admissions with STEMI.
Persisting T2 hyperintensity (binary, yes or no) was asso-
ciated with the occurrence of all-cause death or heart failure 
(hazard ratio, 4.31; 95% confidence interval, 1.00–18.67; 
P=0.051); however, the association was not statistically sig-
nificant. Persisting T2 hyperintensity was not associated with 
MACE (Figure III in the Data Supplement).
The change in infarct zone T2 (1 ms change) was asso-
ciated with all-cause death or heart failure (hazard ratio, 
1.15; 95% confidence interval, 1.05–1.27; P=0.004) and 
with MACE (hazard ratio, 1.14; 95% confidence interval, 
1.03, 1.27; P=0.013). Similar results were observed when 
considering a 10 ms change in infarct zone T2 (all-cause death 
or heart failure hazard ratio, 3.77; 95% confidence interval, 
1.58–8.97; P=0.003: MACE hazard ratio, 3.60; 95% confi-
dence interval, 1.42–9.15; P=0.007).
Discussion
We present a natural history study of the changes in infarct 
zone T2 over time and prognostic significance over 4 years in 
a large unselected cohort of STEMI patients.
The main findings are as follows: (1) T2 hyperintensity 
persisted in approximately two thirds of patients at 6 months 
post-STEMI; (2) infarct zone T2 decreased in the long term 
Figure 3. Change in infarct zone T2 vs 
infarct zone T2 at baseline. Infarct zone 
T2 at baseline was negatively associated 
with the change in infarct zone T2 at 6 
mo.
Table 3. Binary Logistic Regression Analysis for Associations 
With Adverse Remodeling at 6 Months Post-STEMI in 283 
Patients
Multivariable Associations Odds Ratio (95% CI) P Value
Patient characteristics, angiographic data, and persistent infarct zone T2 
hyperintensity
  Persistent T2 hyperintensity 21.91 (2.75–174.29) 0.004
Patient characteristics, angiographic data, and change in infarct zone T2 
(1 ms change)
  Change in infarct zone T2, 1 ms 1.22 (1.10–1.35) <0.001
  Baseline infarct zone T2, ms 1.20 (1.08–1.35) 0.001
Patient characteristics, angiographic data, and change in infarct zone  
T2 (10 ms change)
  Change in infarct zone T2, 10 ms 3.45 (1.53–7.77) 0.003
  Baseline infarct zone T2, ms 1.13 (1.02– 1.24) 0.015
Only statistically significant variables are reported. All variables included 
in the model are described in the Data Supplement. The odds ratio (95% CIs) 
indicates odds of adverse remodeling at 6 mo given exposure to the independent 
variable. CI indicates confidence intervals; STEMI, ST-segment–elevation 
myocardial infarction; and T2, transverse relaxation time.
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in most patients, and the decrease was larger in patients with 
higher infarct zone T2 at baseline; (3) persisting T2 hyper-
intensity was associated with electrocardiographic, angio-
graphic, CMR, and biochemical markers of STEMI severity 
including the initial size of infarction, presence of microvas-
cular obstruction, the myocardial salvage index, peak tropo-
nin, and NT-proBNP; (4) persistent T2 hyperintensity and 
the change in infarct zone T2 were associated with adverse 
remodeling and worsening LV function; and (5) the change 
in infarct zone T2 was associated with adverse health out-
comes. T2 hyperintensity in the infarct zone that persists at 6 
months post-STEMI is an adverse prognostic sign and pres-
ents a mechanistic explanation for worsening LV volumes 
and function.
Direct comparison with previous studies7–10 is qualified 
by differences in sample size and imaging methods. These 
previous studies have defined persisting T2 hyperintensity as 
edema; however, strong evidence that elevated infarct zone 
T2 at 6 months post-STEMI represents edema is lacking. 
Histological studies validating T2 signal as a representation of 
edema have been focused on the acute phase post-STEMI.20–22 
Infarct zone edema as a cause of persisting T2 hyperinten-
sity at 6 months cannot be excluded; however, other causes of 
increased myocardial mobile water content such as myocar-
dial fat should be considered.
The incidence of persistent T2 hyperintensity in the pres-
ent study was high (two thirds of patients) in comparison to 
some9,10 but not all prior recent studies.7,8 In those studies, the 
numbers of participants with paired data were limited (n=10–
62)7–10 implying imprecision.
Ripa et al7 found that myocardial T2 hyperintensity (defined 
as edema) persisted in 51 of 54 (94%) STEMI patients using 
T2 STIR imaging. The average number of affected segments 
per patient decreased by 4.5 segments at 6 months. Persistent 
edema was not associated with LV ejection fraction.
Nilsson et al8 identified a prevalence of high T2 at 6 
months which was comparable with our result (60%); how-
ever, this analysis was performed on a small sample, using 
T2 STIR imaging, and clinical and prognostic information 
was limited. Dark blood STIR edema imaging is a qualita-
tive technique11 with reduced diagnostic accuracy, when com-
pared with quantitative T2 mapping.12 The authors speculate 
that T2 hyperintensity may represent edema or an alternative 
process, such as hemoglobin breakdown products or increased 
unbound water.8
Dall’Armellina et al9 used bright blood T2-weighted 
CMR (n=23 [77%] with paired data). They found that 35% 
of myocardial segments had evidence of edema acutely, and 
the proportion of edematous segments reduced to 6%, with a 
small number of cases having infarct zone edema at 6 months. 
They found that a reduction in edema was associated with an 
improvement in wall motion score index.
Zia et al10 used T2 mapping and found that infarct zone 
T2 signal equalizes with remote zone T2 signal at 6 months 
suggesting complete recovery of myocardial edema. There 
are some reasons why the results of this article may be so 
different to those we present. The sample size was limited 
(n=62 compared with our n=283).10 The methodology refers 
to infarct segment rather than zone.10 If infarct T2 signal has 
been measured across an entire myocardial segment, then 
that segment may also contain unaffected myocardium (and 
hypointense core) and therefore bias the results by averaging 
the signal across 2 myocardial states.
Our study is the first and largest to use contemporary, 
quantitative methods to identify the incidence and clinical sig-
nificance of persistent T2 hyperintensity in a cohort of near-
consecutive patients with acute STEMI. Our study presents 
new insights. The adverse clinical significance of persistent 
T2 hyperintensity was underscored by its associations with 
the initial STEMI severity and LV remodeling, and the valid-
ity of our observations is enhanced given that the T2 maps 
were of diagnostic quality in nearly all patients.
We saw that there was a larger extent of acute microvascu-
lar obstruction in those with persisting T2 hyperintensity, and 
there was also an association between the extent of microvas-
cular obstruction and the extent of myocardial edema acutely. 
The relationship between microvascular obstruction and 
myocardial edema may provide a mechanistic explanation 
into the persistence of T2 hyperintensity, specifically because 
evidence has shown myocardial hemorrhage, which is related 
to microvascular obstruction, leads to iron driven inflamma-
tion.23,24 We also observed worsening LV ejection fractions in 
patients with persisting T2 hyperintensity, which is in keep-
ing with previous reports of edema and attenuated strain.25
Previous research from this cohort suggests that there 
is a significant difference in remote zone T2 between the 
2 time points,26,27 which may be explained by the larger 
sample size in the present study (n=30 in Carrick et al26 and 
n=131 in Carberry et al27). Persisting T2 hyperintensity may 
reflect the natural history of infarct healing3 and inflamma-
tion,28 and potentially, latency of edema within the infarct 
zone to dissipate, especially if water content is substantially 
increased acutely. Nonetheless, we observed that persistent 
T2 hyperintensity has adverse prognostic implications based 
on its association with LV remodeling and health outcome. 
The reason why the change in infarct zone T2 was associ-
ated with MACE and persisting T2 hyperintensity was not 
explained by the nature of the data. Dichotomizing a con-
tinuous variable can reduce statistical power. In addition, our 
results may simply reflect the fact that the absolute change 
in T2 signal in the infarct zone is more predictive of MACE 
than the presence or absence of T2 hyperintensity. Because 
the analysis was limited by the event rate, further research 
is warranted.
Limitations
Because of the length of the imaging protocol, we restricted 
other imaging methods, such as for myocardial fat. The sur-
vival analysis was limited by the absolute number of heart 
failure and all-cause death events (n=19) and MACE events 
(n=16), so these results should be interpreted carefully and 
taken as hypothesis generating.
Conclusions
Infarct zone T2 hyperintensity persisted at 6 months in 
approximately two thirds of STEMI patients. Persistent T2 
hyperintensity was prognostically important because it was 
associated with markers of STEMI severity and adverse LV 
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remodeling. The change in infarct zone T2 signal as a con-
tinuous variable was associated with health outcome. Whether 
T2 hyperintensity at 6 months represents edema or another 
process is uncertain and merits further discussion and study. 
Further studies are warranted to assess whether or not infarct 
zone T2 may track the response to therapy in STEMI patients 
and thus represent a therapeutic target for use in clinical trials.
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CLINICAL PERSPECTIVE
In survivors of acute ST-segment–elevation myocardial infarction, edema within the infarct zone is associated with the initial 
extent of myocardial jeopardy, the size of infarction, and prognosis. Edema impairs myocardial contractility by reducing the 
binding efficiency of actin–myosin filaments leading to reduced force generation in affected cardiomyocytes. There is uncer-
tainty about the natural history and clinical significance of the persistence of T2 hyperintensity because previous studies 
were limited by sample size or method of detection. We present a natural history study of the change in infarct zone T2 signal 
over time and prognostic significance over 4 years in a large unselected cohort of ST-segment–elevation myocardial infarc-
tion patients and using contemporary, quantitative T2-mapping techniques. Infarct zone T2 hyperintensity was present at 6 
months in approximately two thirds of ST-segment–elevation myocardial infarction patients. Persistent T2 hyperintensity 
was prognostically important because it was associated with markers of MI severity and adverse left ventricular remodeling. 
Whether T2 hyperintensity at 6 months represents edema or another process is uncertain and merits further discussion and 
study. The change in infarct zone T2 signal as a continuous variable was associated with health outcome. Further studies are 
warranted to assess whether or not infarct zone T2 may track the response to therapy in ST-segment–elevation myocardial 
infarction patients and thus represent a therapeutic target for use in clinical trials.
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Supplementary Methods 
Setting and study populations 
ST-elevation myocardial infarction patients 
We performed a longitudinal cohort study in a regional cardiac center between 11 May 2011 
and 22 November 2012. Patients with acute ST-elevation myocardial infarction (STEMI) 
were consecutively screened for suitability and those recruited provided written informed 
consent. Inclusion criteria were an indication for primary percutaneous coronary intervention 
(PCI) or thrombolysis for STEMI1. Exclusion criteria were contraindications to contrast-
enhanced cardiac magnetic resonance (CMR) imaging. For the purposes of this analysis, 
STEMI patients who experienced a recurrent MI or had an additional PCI following the index 
procedure were not included since these events could influence myocardial T2 (ms) during 
the intervening period. STEMI management followed current guidelines1,2. The study was 
approved by the National Research Ethics Service (Reference 10-S0703-28) and was 
publically registered (NCT02072850). The flow diagram for the study is shown in 
Supplementary Figure 1. 
Screening, enrolment, and data collection were prospectively performed by cardiologists in 
the cardiac catheterization laboratories of the Golden Jubilee National Hospital, Glasgow, 
United Kingdom. This hospital is a regional referral center for primary and rescue PCI. The 
hospital provides clinical services for a population of 2.2 million. A screening log was 
recorded, including patients who did not participate in the cohort study. 
Coronary angiogram acquisition and analyses 
Coronary angiograms were acquired during usual care with cardiac catheter laboratory X-ray 
(Innova®) and IT equipment (Centricity®) made by GE Healthcare.  
 4 
Percutaneous coronary intervention 
Consecutive admissions with acute STEMI referred for emergency PCI were screened for the 
inclusion and exclusion criteria. During ambulance transfer to the hospital, the patients 
received 300 mg of aspirin, 600 mg of clopidogrel and 5000 IU of unfractionated heparin1,2. 
The initial primary PCI procedure was performed using radial artery access. A conventional 
approach to primary PCI was adopted in line with usual care in our hospital1,2. Conventional 
bare metal and drug eluting stents were used in line with guideline recommendations and 
clinical judgment. The standard transcatheter approach for reperfusion involves minimal 
intervention with aspiration thrombectomy only or minimal balloon angioplasty (e.g. a 
compliant balloon sized according to the reference vessel diameter and inflated at 4-6 
atmospheres 1-2 times). During PCI, glycoprotein IIbIIIa inhibitor therapy was initiated with 
high dose tirofiban (25 µg/kg/bolus) followed by an intravenous infusion of 0.15 µg/kg/min 
for 12 hours, according to clinical judgment and indications for bail-out therapy1,2. No reflow 
was treated according to contemporary standards of care with intra-coronary nitrate (i.e. 200 
µg) and adenosine (i.e. 30 – 60 µg)1,2, as clinically appropriate. In patients with multivessel 
coronary disease, multivessel PCI was not recommended, in line with clinical guidelines1,2. 
The subsequent management of these patients was symptom-guided. 
Angiographic analysis 
The coronary anatomy and disease characteristics of study participants were described based 
on the clinical reports of the attending cardiologist.  
Outcome definitions 
Coronary blood flow can be described based on the visual assessment of coronary blood flow 
revealed by contrast injection into the coronary arteries1,2. TIMI Coronary Flow Grade 0 is no 
 5 
flow, 1 is minimal flow past obstruction, 2 is slow (but complete) filling and slow clearance, 
and 3 is normal flow and clearance. 
CMR acquisition 
CMR imaging was performed on a Siemens MAGNETOM Avanto (Erlangen, Germany) 1.5-
Tesla scanner with a 12-element phased array cardiac surface coil.  
Myocardial native longitudinal relaxation time (T1) reflects tissue water content and 
cellularity3. T1-mapping was performed pre- and 15 minutes post-gadolinium contrast 
administration. T1 maps were acquired in 3 short-axial slices (basal, mid and apical), using a 
modified look-locker inversion-recovery (MOLLI) investigational prototype sequence 
(Work-in-Progress (WIP) method 448, Siemens Healthcare)4–6 that incorporates an automatic 
registration algorithm based on a previously described approach7. The MOLLI T1 cardiac-
gated acquisition involved three inversion-recovery prepared look locker experiments 
combined within one protocol (3 (3) 3 (3) 5)5. The CMR parameters were: bandwidth ~1090 
Hz/pixel; flip angle 35°; echo time (TE) 1.1 ms; T1 of first experiment 100 ms; TI increment 
80 ms; matrix 192 x 124 pixels; spatial resolution 2.2 x 1.8 x 8.0 mm; slice thickness 8 mm; 
scan time 17 heartbeats. 
Myocardial transverse relaxation time (T2) directly reflects tissue water content and 
mobility8,9. T2-mapping (WIP method 447, Siemens Healthcare) was acquired in contiguous 
short axis slices covering the whole ventricle, using an investigational prototype T2-prepared 
(T2P) TrueFisp sequence8,9. The CMR parameters were: bandwidth ~947 Hz/pixel; flip angle 
70°; T2 preparations: 0 ms, 24 ms, and 55 ms respectively; matrix 160 x 105 pixels; spatial 
resolution 2.6 x 2.1 x 8.0 mm; slice thickness 8 mm. 
Late gadolinium enhancement images covering the entire left ventricle (LV) were acquired 
10-15 minutes after intravenous injection of 0.15 mmol/kg of gadoterate meglumine (Gd2+-
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DOTA, Dotarem, Guebert S.A.) using segmented phase-sensitive inversion recovery (PSIR) 
turbo fast low-angle shot10. Typical imaging parameters were: bandwidth ~130 Hz/pixel, flip 
angle 25°, TE 3.36 ms, matrix 192 x 256 pixels, echo spacing 8.7ms and trigger pulse 2. The 
voxel size was 1.8 x 1.3 x 8 mm3. Inversion times were individually adjusted to optimize 
nulling of apparently normal myocardium (typical values, 200 to 300 ms). 
CMR image analyses 
The images were analysed on a Siemens work-station by observers with at least 3 years CMR 
experience (N.A., D.C., I.M, S.R.). All of the images were reviewed by experienced CMR 
cardiologists (C.B., N.T.). LV dimensions, volumes and ejection fraction were quantified 
using computer assisted planimetry (syngo MR®, Siemens Healthcare, Erlangen, Germany). 
All scan acquisitions were spatially co-registered.  
ECV measurement 
LV contours were delineated on the best spatially matched raw T1 image and copied onto 
color-coded spatially co-registered maps. Regions of interest were drawn in infarcted 
myocardium surrounding core, remote myocardium and LV blood pool. Hematocrit (HCT) 
was measured at the time of scanning. Extracellular volume (ECV) was calculated as a ratio 
of corresponding T1 values measured pre- and post- contrast in each of the regions of 
interest. ECV was calculated using ECV = (1-HCT) × λ, where Lambda 
(λ)=ΔR1myocardium/ΔR1blood, ΔR1=R1post-contrast-R1pre-contrast and R1=1/T111,12.  
Infarct definition and size 
The territory of infarction was delineated using a signal intensity threshold of >5 standard 
deviations (SD) above a remote reference region and expressed as a percentage of total LV 
mass13. Infarct regions with evidence of microvascular obstruction were included within the 
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infarct area and the area of microvascular obstruction was assessed separately and also 
expressed as a percentage of total LV mass. 
Reference ranges 
Reference ranges used in the laboratory were 105 – 215 g for LV mass in men, 70 – 170 g for 
LV mass in women, 77 – 195 ml for LV end-diastolic volume in men, 52 – 141 ml for LV 
end-diastolic volume in women, 19 – 72 ml for LV end-systolic volume in men and 13 – 51 
ml for LV end-systolic volume in women.  
Electrocardiogram 
A 12 lead ECG was obtained before coronary reperfusion and 60 minutes afterwards with 
Mac-Lab® technology (GE Healthcare) in the catheter laboratory and a MAC 5500 HD 
recorder (GE Healthcare) in the Coronary Care Unit. The ECGs were acquired by trained 
cardiology staff. The ECGs were de-identified and transferred to the local ECG management 
system. The ECGs were then analysed by the University of Glasgow ECG Core Laboratory 
which is certified to ISO 9001: 2008 standards as a UKAS Accredited Organisation.  
The extent of ST-segment resolution on the ECG assessed 60 minutes after reperfusion 
compared to the baseline ECG before reperfusion1 was expressed as complete (≥70%), 
incomplete (>30% to < 70%) or none (≤30%). 
Biochemical measurement of infarct size 
Troponin T was measured (Elecsys Troponin T, Roche) as a biochemical measure of infarct 
size. The high sensitive assay reaches a level of detection of 5 pg/ml and achieves less than 
10%variation at 14 pg/ml corresponding to the 99th percentile of a reference population. A 
blood sample was routinely obtained 12 – 24 hours after hospital admission, and again 
between 0700 - 0900 hours during the first two days of the index hospitalization. 
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Biochemical measurement of LV remodeling 
Serial systemic blood sample were obtained immediately after reperfusion in the cardiac 
catheterization laboratory, and subsequently between 0600 - 0700 hrs each day during the 
initial in-patient stay in the Coronary Care Unit.  
NT-proBNP, a biochemical measure of LV wall stress, was measured in a research laboratory 
using an electrochemiluminescence method (e411, Roche) and the manufacturers calibrators 
and quality control material. The limit of detection is 5 pg/ml. Long-term coefficient of 
variations of low and high controls are typically <5%, and were all within the manufacturers 
range. 
Research Management 
The study was conducted in line with Guidelines for Good Clinical Practice (GCP) in Clinical 
Trials14.  
Trial management included a Trial Management Group, and an independent Clinical Trials 
Unit. Day to day study activity was coordinated by the Trial Management Group who was 
responsible to the Sponsor which was responsible for overall governance and that the trial 
was conducted according to GCP standards.  
Health outcomes 
We prespecified adverse health outcomes that are pathophysiologically linked with STEMI. 
The primary composite outcome was major adverse cardiac events (MACE) defined as 
cardiac death, non-fatal myocardial infarction or heart failure hospitalization following the 6-
month CMR scan. All-cause death or heart failure (heart failure hospitalization or 
defibrillator implantation) following the 6-month CMR scan was a secondary outcome. 
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Research staff screened for events from enrolment by checking the medical records and by 
contacting patients and their primary and secondary care physicians as appropriate. Each 
serious adverse event was reviewed by a cardiologist who was independent of the research 
team and blinded to all of the clinical and CMR data. The serious adverse events were 
defined according to standard guidelines15. 
Statistics 
Continuous variables are described as mean±SD, if normally distributed, and median (Q1, 
Q3) otherwise. Categorical variables are described as n (%). Variables are described overall 
and by presence or absence of persistent T2 hyperintensity. Patient and angiographic 
characteristics and CMR findings were compared between groups with presence or absence 
of persistent T2 hyperintensity using independent sample t-tests or Mann-Whitney tests, as 
appropriate. Binary logistic regression was used to identify associates of persistent T2 
hyperintensity. Multivariable linear regression analyses using the enter method were 
performed to identify associates of the change in infarct zone T2 and LV parameters. Linear 
regression assumptions were verified using standardized residual plots.  
Random effects models were used to compute inter-rater reliability measures (inter-class 
correlation coefficient (ICC)) for the reliability of infarct zone T2 values measured 
independently by 2 observers in 20 randomly selected patients from the cohort.  
Cox proportional hazards regression was used to explore potential associations between 
persisting T2 hyperintensity and health outcome. The proportional hazards assumption was 
verified using log-minus-log plots. For these plots, continuous variables were categorized as 
above and below the median. 
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All p-values were 2-sided. A p-value >0.05 indicated the absence of a statistically significant 
effect. The natural log was used in transformations of variables. Analyses were performed 
using SPSS version 22 for Windows (SPSS, Inc., Chicago, Illinois), or R v3.3.0.  
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Supplementary Results 
CMR findings 
The full list of CMR findings are summarized in Supplementary Table 1. 
The association between change in LV ejection fraction and persisting T2 hyperintensity and 
the change in infarct zone T2 is shown in Supplementary Table 2. 
Infarct zone T2 inter-observer reliability 
Infarct zone T2 in a subgroup of 20 randomly chosen patients was independently measured 
by two observers. The intra-class correlation coefficient for reliability of infarct zone T2 was 
0.92 (95% confidence interval (CI): 0.75, 0.97); p<0.001. Bland-Altman plots 
(Supplementary Figure 2) showed no evidence of bias. The coefficient of variation for infarct 
zone T2 was 7.4%. 
Persistent T2 hyperintensity and extracellular volume 
Infarct zone ECV was measured in 127 patients at baseline and 124 patients at follow-up 
(n=124 paired measurements). The characteristics of these patients were similar to the whole 
cohort (data not shown). Infarct zone ECV and T2 were associated at baseline (0.14 (0.04, 
0.24); p=0.007) which likely reflects the early increase in infarct zone extracellular water 
content. Additionally, infarct zone ECV at 6 months was higher in patients with persisting T2 
hyperintensity (Table 2). There was an association between the change in infarct zone ECV at 
6 months compared to baseline and the change in T2 in the infarct zone (0.15 (0.05, 0.24); 
p=0.002; n=124). The directions of change in infarct zone T2 and infarct zone ECV were 
independent (Chi square; p=0.420). In the majority of patients, infarct zone T2 decreased 
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over time, which means those who had a smaller decrease in infarct zone T2 had a larger 
increase in infarct zone ECV. 
Since ECV may also reflect extracellular collagen volume fraction16, progressive 
extracellular fibrosis within the infarct zone may lead to an increase in ECV in the chronic 
phase post-STEMI. After adjustment for infarct zone ECV, infarct zone T2 was no longer a 
multivariable associate of LV remodeling. Accepting some loss of statistical power in this 
subset analysis, the potential explanations for this result may include 1) progressive infarct 
zone fibrosis is associated with persistent T2 hyperintensity at 6 months; 2) extracellular 
rather than intracellular edema is prominent in pathological remodeling post-MI and; 3) 
measurement error, since hematocrit, which is required to calculate ECV, may not be 
uniformly distributed in systemic blood and injured capillaries may allow varying amounts of 
formed blood elements to occupy the microvascular compartment.  
Associates with adverse remodeling at 6 months 
The clinical characteristics that were included in the multivariable model with adverse 
remodeling at 6 months were BMI (p=0.589), age (p=0.502), male sex (p=0.812), previous 
MI (p=0.708), previous PCI (p=0.347), diabetes mellitus (p=0.432), previous angina 
(p=0.879), hypertension (p=0.437), hypercholesterolemia (p=0.879), cigarette smoking 
(p=0.117), no ST-segment resolution vs. complete or partial ST-segment resolution 
(reference category) (p=0.882), TIMI coronary flow grade 0/1 pre-PCI vs. TIMI coronary 
flow grade 2/3 pre-PCI (reference category) (p=0.280), TIMI coronary flow grade 0/1/2 post-
PCI vs. TIMI coronary flow grade 3 post-PCI (reference category) (p=0.295) systolic blood 
pressure at initial angiography per 10mmHg (p=0.419), heart rate (p=0.818), symptom onset 
to reperfusion time (p=0.258), percentage stenosis of culprit artery (p=0.274). 
The multivariable predictors are described in Table 3 in the main paper. 
 13 
Persistent T2 hyperintensity and health outcomes 
Kaplan-Meier plots for the association between persisting T2 hyperintesity and all-cause 
death or heart failure and major adverse cardiac events are shown in Supplementary Figure 3. 
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Supplementary Figures 
Supplementary Figure 1. CONSORT flow diagram. 
Supplementary Figure 2. Bland-Altman plot for inter-observer variability in infarct zone T2 
measurement. 
Supplementary Figure 3. Kaplan-Meier plots for the association between persisting T2 
hyperintesity and A) all-cause death or heart failure (Log rank = 0.115) and B) major adverse 
cardiac events (Log rank = 0.212).  
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Supplementary Figure 1.   
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Supplem
entary T
ables 
Supplem
entary T
able 1. C
M
R
 findings in 283 patients grouped according to the presence or absence of persistent T2 hyperintensity revealed 
by T2-m
apping at 6 m
onths post-STEM
I. 
C
haracteristics 
A
ll patients 
N
o persistent T2 hyperintensity 
Persistent T2 hyperintensity 
P-value* 
 
n=283 
n=94 (33%
) 
n=189 (67%
) 
 
C
M
R findings 2 days post-M
I 
 
 
 
 
LV
 ejection fraction, %
 
55±10 
57±10 
55±10 
0.071 
LV
 end-diastolic volum
e, m
l 
 
 
 
 
M
en 
161±31 
155±30 
164±31 
0.036 
W
om
en 
124±25 
130±23 
121±25 
0.172 
LV
 end-systolic volum
e, m
l 
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 M
en 
74±26 
69±25 
78±26 
0.014 
W
om
en 
54±18 
57±18 
52±17 
0.225 
LV
 m
ass, g 
 
 
 
 
M
en 
144±33 
137±29 
148±34 
0.028 
W
om
en 
97±21 
101±17 
95±23 
0.216 
Edem
a and infarct characteristics 
 
 
 
 
M
yocardial edem
a, %
 LV
 m
ass 
32±12 
30±13 
33±11 
0.050 
Infarct size, %
 LV
 m
ass 
18±13 
13±13 
20±13 
<0.001 
M
yocardial salvage, %
 LV
 m
ass 
19±9 
21±10 
18±8 
0.033 
M
yocardial salvage index, %
 LV
 m
ass 
63±24 
73±24 
58±23 
<0.001 
Late m
icrovascular obstruction present, n (%
) 
138 (49) 
33 (35) 
105 (56) 
0.002 
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 Late m
icrovascular obstruction, %
 LV
 m
ass 
2.6±4.6 
1.5±3.6 
3.1±4.9 
0.004 
M
yocardial T1 and T2 values 
 
 
 
 
T1 rem
ote, m
s 
960±26 
958±25 
961±26 
0.354 
T1 infarct, m
s 
1097±52 
1093±49 
1099±53 
0.338 
T1 hypointense core present, n (%
) 
137 (48) 
33 (35) 
104 (55) 
0.002 
T1 hypointense infarct core, m
s 
996±60 
999±56 
995±61 
0.702 
T2 rem
ote, m
s 
49.7±2.1 
49.8±2.2 
49.7±2.1 
0.811 
T2 infarct, m
s 
66.3±6.1 
64.4±5.7 
67.3±6.1 
<0.001 
T2 hypointense core present, n (%
) 
165 (58) 
41 (44) 
124 (66) 
0.001 
T2 hypointense infarct core, m
s 
54.1±4.8 
53.9±5.1 
54.2±4.7 
0.698 
M
yocardial EC
V values at baseline 
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 EC
V
 rem
ote (all subjects), %
 
25.6±2.9 
25.6±2.8 
25.6±3.0 
0.995 
M
en 
25.2±2.9 
25.0±2.7 
25.3±2.9 
0.612 
W
om
en 
27.0±2.6 
27.1±2.4 
26.8±2.8 
0.763 
EC
V
 infarct, %
 
56.0±11.7 
52.8±12.9 
57.7±10.7 
0.024 
EC
V
 hypointense infarct core, %
 
43.2±12.6 
44.8±15.1 
42.5±11.7 
0.537 
C
M
R findings at 6 m
onths 
 
 
 
 
LV
 ejection fraction at 6 m
onths, %
 
62±9 
65±8 
61±10 
<0.001 
LV
 end-diastolic volum
e at 6 m
onths, m
l 
 
 
 
 
M
en 
169±42 
151±31 
177±45 
<0.001 
W
om
en 
127±30 
125±22 
128±34 
0.627 
LV
 end-systolic volum
e at 6 m
onths, m
l 
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 M
en 
68±35 
54±19 
74±38 
<0.001 
W
om
en 
46±18 
45±18 
47±18 
0.550 
A
dverse rem
odeling, n (%
) 
32 (12) 
1 (1) 
31 (17) 
<0.001 
Infarct characteristics at 6 m
onths 
 
 
 
 
Infarct size at 6 m
onths, %
 LV
 m
ass 
13±10 
9±9 
15±10 
<0.001 
M
yocardial T1 and T2 values at 6 m
onths 
 
 
 
 
T1 rem
ote at 6 m
onths, m
s 
957±29 
957±28 
958±29 
0.713 
T1 infarct at 6 m
onths, m
s 
1058±66 
1035±59 
1068±67 
<0.001 
T2 rem
ote at 6 m
onths, m
s 
49.7±2.3 
50.3±2.5 
49.4±2.1 
0.001 
T2 infarct at 6 m
onths, m
s 
56.8±4.5 
53.5±3.4 
58.5±4.0 
<0.001 
M
yocardial EC
V values at 6 m
onths 
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 EC
V
 rem
ote at 6 m
onths (all subjects), %
 
25.6±2.7 
25.5±2.6 
25.7±2.8 
0.519 
M
en 
25.3±2.7 
25.0±2.6 
25.4±2.7 
0.288 
W
om
en 
26.8±2.5 
26.9±2.1 
26.8±2.9 
0.917 
EC
V
 infarct at 6 m
onths, %
 
51.6±11.1 
47.5±11.0 
53.7±10.5 
<0.001 
Footnote: A
bbreviations: C
M
R
 = cardiac m
agnetic resonance, EC
V
 = extracellular volum
e, LV
 = left ventricle, T1 = longitudinal relaxation 
tim
e, T2 = transverse relaxation tim
e. D
ata are given as n (%
) or m
ean±SD
 as appropriate. *P-values w
ere obtained from
 tw
o-sam
ple t-test, 
M
ann W
hitney test or Fisher’s test. 
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Supplementary Table 2. Linear regression analysis for associations with the change in LV 
ejection fraction at 6 months post-STEMI.  
Multivariable associations coefficient (95% CI) p value 
Patient characteristics, angiographic data and persistent T2 hyperintensity 
Persistent T2 hyperintensity -2.53 (-4.39, -0.68) 0.008 
Previous MI 6.29 (1.75, 10.83) 0.007 
LV ejection fraction at baseline, % -0.38 (-0.48, -0.29) <0.001 
Patient characteristics, angiographic data and change in infarct zone T2 (1 ms change) 
Change in infarct zone T2, 1 ms -0.45 (-0.65, -0.26) <0.001 
Percentage stenosis of culprit artery, % -0.14 (-0.24, -0.04) 0.007 
Previous MI 5.47 (1.07, 9.86) 0.015 
Hypertension 2.24 (0.31, 4.17) 0.023 
Baseline infarct zone T2, ms -0.52 (-0.73, -0.31) <0.001 
LV ejection fraction at baseline, % -0.39 (-0.49, -0.30) <0.001 
Patient characteristics, angiographic data and change in infarct zone T2 (10 ms change) 
Change in infarct zone T2, 10 ms -2.37 (-4.00, -0.75) 0.004 
Percentage stenosis of culprit artery, % -0.16 (-0.26, -0.05) 0.003 
Previous MI 5.65 (1.14, 10.16) 0.014 
Baseline infarct zone T2, ms -0.36 (-0.55, -0.16) <0.001 
LV ejection fraction at baseline, % -0.39 (-0.48, -0.29) <0.001 
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Footnote: Abbreviations: CI = confidence intervals, LV = left ventricle, MI = myocardial 
infarction, T2 = transverse relaxation time. The coefficient (95% confidence intervals) 
indicates the magnitude and direction of the difference in change in LV ejection fraction (%) 
for the patient characteristic (binary or continuous). 
The clinical characteristics that were included in the multivariable model with adverse 
remodeling at 6 months were BMI (p=0.574), age (p=0.354), male sex (p=0.460), previous 
PCI (p=0.808), diabetes mellitus (p=0.671), previous angina (p=0.402), hypertension 
(p=0.076), hypercholesterolemia (p=0.468), cigarette smoking (p=0.246), no ST-segment 
resolution vs. complete or partial ST-segment resolution (reference category) (p=0.746), 
TIMI coronary flow grade 0/1 pre-PCI vs. TIMI coronary flow grade 2/3 pre-PCI (reference 
category) (p=0.764), TIMI coronary flow grade 0/1/2 post-PCI vs. TIMI coronary flow grade 
3 post-PCI (reference category) (p=0.529) systolic blood pressure at initial angiography per 
10mmHg (p=0.578), heart rate (p=0.782), symptom onset to reperfusion time (p=0.617).  
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